Quick Takeaways
- MDGL - MADRIGAL PHARMACEUTICALS, INC. has 23 insiders with reported activity on this page.
- Net insider value flow over the last year: -$120,435,124.
- Recent transaction rows are available for direct filing-level review.
- Info
- Insider Trading
- Financials
- Holders
Insider Transactions Reported by 23 Insiders of MADRIGAL PHARMACEUTICALS, INC.
- Symbol
- MDGL on Nasdaq
- Location
- West Conshohocken, PA
What Changed
- Buy value: $61,921,024; sell value: $182,356,148.
- Net share flow: -276,004.
Why This Matters
- This page gives a plain-language issuer insider context before you inspect transaction-level evidence.
- Use the filing links below to verify timestamps, codes, and ownership impacts directly from SEC forms.
Official SEC Source
Insider trading overview
Last 12 monthsNet insider flow leans to selling over the last 12 months. Net value: -$120,435,124.
Buys
$61,921,024
Shares: 165,683
Insiders: 1
Sells
$182,356,148
Shares: 441,687
Insiders: 8
Net
-$120,435,124
Shares: -276,004
Insiders: -7
| Window (months) | Buy shares | Sell shares | Buy $ | Sell $ | Net $ |
|---|---|---|---|---|---|
| 0-3 | 0 | 55,612 | $0 | $28,325,956 | -$28,325,956 |
| 3-6 | 0 | 77,056 | $0 | $41,324,501 | -$41,324,501 |
| 6-9 | 165,683 | 309,019 | $61,921,024 | $112,705,691 | -$50,784,667 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
MADRIGAL PHARMACEUTICALS, INC. executives and other stock owners filed with the SEC include:
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP | Director | $764,076,617 | +$61,921,024 | +8.8% | Filing P/S | 18 Aug 2025 |
| Rebecca Taub | Director | $515,402,843 | -$48,813,121 | -8.7% | Mixed | 06 Mar 2026 |
| Paul A. Friedman | Director | $484,919,577 | -$101,802,886 | -17% | Mixed | 09 Jan 2026 |
| Fred B. Craves | Director | $122,538,572 | Mixed | 12 Mar 2025 | ||
| William John Sibold | President and CEO, Director | $69,900,418 | -$9,167,176 | -12% | Filing P/S | 04 Mar 2026 |
| David Soergel | Chief Medical Officer | $5,819,570 | Mixed | 04 Mar 2026 | ||
| Alex G. Howarth | Chief Financial Officer | $5,741,877 | Mixed | 23 Jan 2024 | ||
| Carole Huntsman | Chief Commercial Officer | $5,482,182 | -$1,713,308 | -24% | Filing P/S | 04 Mar 2026 |
| Mardi Dier | EVP and CFO | $5,466,248 | -$3,772,798 | -41% | Filing P/S | 04 Mar 2026 |
| Brian J. Lynch | SVP and General Counsel | $5,332,092 | Mixed | 23 Jan 2024 | ||
| Kelley Shannon T. | General Counsel | $5,242,887 | -$979,298 | -16% | Filing P/S | 04 Mar 2026 |
| Remy Sukhija | Chief Commercial Officer | $3,659,044 | Mixed | 16 Jan 2023 | ||
| Robert E. Waltermire | Senior VP, Chief Pharma Dev. | $1,995,798 | Mixed | 05 Mar 2025 | ||
| Rita Thakkar | Chief Accounting Officer | $1,396,451 | Mixed | 15 Jan 2026 | ||
| Kenneth Bate | Director | $1,289,808 | -$11,679,363 | -90% | Filing P/S | 05 Nov 2025 |
| James M. Daly | Director | $713,414 | Mixed | 20 Jun 2025 | ||
| BAY CITY CAPITAL LLC | 10%+ Owner | $307,583 | Mixed | 03 Dec 2021 | ||
| Jacqualyn A. Fouse | Director | $297,912 | Mixed | 20 Jun 2025 | ||
| Daniel J. Brennan | Director | $292,652 | Mixed | 01 Aug 2025 | ||
| Richard S. Levy | Director | $203,849 | -$4,428,198 | -96% | Mixed | 23 Feb 2026 |
| Keith R. Gollust | Director | Mixed | 16 Jun 2022 | |||
| David Milligan V | Director | Mixed | 16 Jun 2022 | |||
| Dr. Raymond Cheong | Director | Mixed | 15 Jun 2023 |
Top shareholders of MADRIGAL PHARMACEUTICALS, INC. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| BAKER BROS. ADVISORS LP |
13F
3/4/5
|
Company · Director |
9.4%
|
2,141,701
|
$1,247,198,160 | — | 31 Dec 2025 | |
| RTW INVESTMENTS, LP |
13F
|
Company |
8.8%
|
1,993,687
|
$1,161,003,688 | — | 31 Dec 2025 | |
| VANGUARD GROUP INC |
13F
|
Company |
7.9%
|
1,808,894
|
$1,053,391,331 | — | 31 Dec 2025 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
7.9%
|
1,807,500
|
$1,052,579,550 | — | 31 Dec 2025 | |
| PAULSON & CO. INC. |
13F
13D/G
|
Company |
7.5%
from 13D/G
|
1,707,522
|
$994,358,361 | — | 31 Dec 2025 | |
| Paul A. Friedman |
13D/G
3/4/5
|
Paul A Friedman, M.D. · Director |
7.8%
|
1,814,831
|
$982,730,986 | $0 | 10 Dec 2025 | |
| Rebecca Taub |
13D/G
3/4/5
|
Rebecca Taub, M.D. · Director |
7.8%
|
1,814,831
|
$982,730,986 | $0 | 10 Dec 2025 | |
| BlackRock, Inc. |
13F
|
Company |
7.2%
|
1,644,750
|
$957,803,431 | — | 31 Dec 2025 | |
| JANUS HENDERSON GROUP PLC |
13F
13D/G
|
Company |
7%
from 13D/G
|
1,584,843
|
$918,203,904 | — | 31 Dec 2025 | |
| STATE STREET CORP |
13F
|
Company |
2.6%
|
583,003
|
$339,505,967 | — | 31 Dec 2025 | |
| WELLINGTON MANAGEMENT GROUP LLP |
13F
|
Company |
2%
|
461,402
|
$268,692,841 | — | 31 Dec 2025 | |
| GEODE CAPITAL MANAGEMENT, LLC |
13F
|
Company |
2%
|
451,743
|
$263,113,834 | — | 31 Dec 2025 | |
| FMR LLC |
13F
|
Company |
1.9%
|
439,398
|
$255,879,233 | — | 31 Dec 2025 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
1.8%
|
416,025
|
$242,267,998 | — | 31 Dec 2025 | |
| Invesco Ltd. |
13F
|
Company |
1.6%
|
365,314
|
$212,736,955 | — | 31 Dec 2025 | |
| WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC |
13F
|
Company |
1.6%
|
354,220
|
$206,276,475 | — | 31 Dec 2025 | |
| PRICE T ROWE ASSOCIATES INC /MD/ |
13F
|
Company |
1.4%
|
313,659
|
$182,658,000 | — | 31 Dec 2025 | |
| GOLDMAN SACHS GROUP INC |
13F
|
Company |
1.3%
|
305,847
|
$178,106,943 | — | 31 Dec 2025 | |
| Polar Capital Holdings Plc |
13F
|
Company |
1.2%
|
270,151
|
$157,319,733 | — | 31 Dec 2025 | |
| ARMISTICE CAPITAL, LLC |
13F
|
Company |
1.2%
|
265,705
|
$154,730,650 | — | 31 Dec 2025 | |
| Hood River Capital Management LLC |
13F
|
Company |
1.1%
|
247,560
|
$144,164,090 | — | 31 Dec 2025 | |
| LORD, ABBETT & CO. LLC |
13F
|
Company |
1.1%
|
244,796
|
$142,555,000 | — | 31 Dec 2025 | |
| ALKEON CAPITAL MANAGEMENT LLC |
13F
|
Company |
1.1%
|
240,000
|
$139,761,600 | — | 31 Dec 2025 | |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC |
13F
|
Company |
0.96%
|
219,099
|
$127,590,112 | — | 31 Dec 2025 | |
| Fred B. Craves |
3/4/5
|
Director |
—
class O/S missing
|
371,076
|
$122,538,572 | — | 12 Mar 2025 | |
| Artisan Partners Limited Partnership |
13F
|
Company |
0.87%
|
198,693
|
$115,706,882 | — | 31 Dec 2025 | |
| NORGES BANK |
13F
|
Company |
0.86%
|
196,393
|
$114,367,500 | — | 31 Dec 2025 | |
| DEUTSCHE BANK AG\ |
13F
|
Company |
0.84%
|
192,109
|
$111,872,756 | — | 31 Dec 2025 | |
| AMERICAN CENTURY COMPANIES INC |
13F
|
Company |
0.81%
|
185,116
|
$107,801,864 | — | 31 Dec 2025 | |
| Pictet Asset Management Holding SA |
13F
|
Company |
0.8%
|
181,949
|
$106,018,005 | — | 31 Dec 2025 | |
| Fiera Capital Corp |
13F
|
Company |
0.74%
|
169,456
|
$98,681,007 | — | 31 Dec 2025 | |
| NORTHERN TRUST CORP |
13F
|
Company |
0.67%
|
151,802
|
$88,400,377 | — | 31 Dec 2025 | |
| MORGAN STANLEY |
13F
|
Company |
0.66%
|
150,462
|
$87,620,476 | — | 31 Dec 2025 | |
| Erste Asset Management GmbH |
13F
|
Company |
0.62%
|
141,100
|
$82,318,617 | — | 31 Dec 2025 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.61%
|
139,618
|
$81,305,146 | — | 31 Dec 2025 | |
| Bank of New York Mellon Corp |
13F
|
Company |
0.6%
|
136,869
|
$79,704,012 | — | 31 Dec 2025 | |
| Point72 Asset Management, L.P. |
13F
|
Company |
0.56%
|
126,435
|
$73,628,158 | — | 31 Dec 2025 | |
| Woodline Partners LP |
13F
|
Company |
0.55%
|
125,659
|
$73,176,262 | — | 31 Dec 2025 | |
| William John Sibold |
3/4/5
|
President and CEO, Director |
—
mixed-class rows
|
180,572
mixed-class rows
|
$69,900,418 | -$9,167,176 | 04 Mar 2026 | |
| Nuveen, LLC |
13F
|
Company |
0.52%
|
118,363
|
$68,927,510 | — | 31 Dec 2025 | |
| DRIEHAUS CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.49%
|
111,666
|
$65,027,578 | — | 31 Dec 2025 | |
| UBS Group AG |
13F
|
Company |
0.45%
|
102,641
|
$59,771,960 | — | 31 Dec 2025 | |
| MPM BioImpact LLC |
13F
|
Company |
0.43%
|
96,780
|
$56,358,865 | — | 31 Dec 2025 | |
| JANE STREET GROUP, LLC |
13F
|
Company |
0.41%
|
93,114
|
$54,224,006 | — | 31 Dec 2025 | |
| D. E. Shaw & Co., Inc. |
13F
|
Company |
0.39%
|
88,554
|
$51,568,536 | — | 31 Dec 2025 | |
| FRANKLIN RESOURCES INC |
13F
|
Company |
0.38%
|
86,076
|
$50,125,498 | — | 31 Dec 2025 | |
| Tri Locum Partners LP |
13F
|
Company |
0.38%
|
86,023
|
$50,094,634 | — | 31 Dec 2025 | |
| RENAISSANCE TECHNOLOGIES LLC |
13F
|
Company |
0.37%
|
83,862
|
$48,836,197 | — | 31 Dec 2025 | |
| ArrowMark Colorado Holdings LLC |
13F
|
Company |
0.36%
|
82,624
|
$48,115,260 | — | 31 Dec 2025 | |
| NEW YORK STATE COMMON RETIREMENT FUND |
13F
|
Company |
0.33%
|
75,933
|
$44,218,823 | — | 31 Dec 2025 |
Recent Insider Transactions by Companies or Individuals for MADRIGAL PHARMACEUTICALS, INC.
Showing up to 300 most recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | Value $ | * Price $ | Shares | Shares Owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| Mardi Dier | MDGL | Common Stock | Sale | -13.7% | $853,993 | $430.87 | -1,982 | 12,490 | 06 Mar 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Sale | -1.02% | $718,316 | $431.94 | -1,663 | 161,829 | 06 Mar 2026 | Direct |
| Kelley Shannon T. | MDGL | Common Stock | Sale | -2.88% | $155,498 | $431.94 | -360 | 12,138 | 06 Mar 2026 | Direct |
| Carole Huntsman | MDGL | Common Stock | Sale | -3.2% | $180,983 | $431.94 | -419 | 12,692 | 06 Mar 2026 | Direct |
| Rebecca Taub | MDGL | Common Stock | Sale | -0.11% | $212,083 | $431.94 | -491 | 452,213 | 06 Mar 2026 | Direct |
| Mardi Dier | MDGL | Common Stock | Award | 56.3% | 5,215 | 14,472 | 04 Mar 2026 | Direct | ||
| Mardi Dier | MDGL | Stock Option (Right to Buy) | Award | 6,519 | 6,519 | 04 Mar 2026 | Direct | |||
| William John Sibold | MDGL | Common Stock | Award | 10.1% | 14,995 | 163,492 | 04 Mar 2026 | Direct | ||
| William John Sibold | MDGL | Stock Option (Right to Buy) | Award | 18,743 | 18,743 | 04 Mar 2026 | Direct | |||
| Kelley Shannon T. | MDGL | Common Stock | Award | 47.4% | 4,017 | 12,498 | 04 Mar 2026 | Direct | ||
| Kelley Shannon T. | MDGL | Stock Option (Right to Buy) | Award | 5,022 | 5,022 | 04 Mar 2026 | Direct | |||
| Carole Huntsman | MDGL | Common Stock | Award | 43.7% | 3,989 | 13,111 | 04 Mar 2026 | Direct | ||
| Carole Huntsman | MDGL | Stock Option (Right to Buy) | Award | 4,986 | 4,986 | 04 Mar 2026 | Direct | |||
| David Soergel | MDGL | Common Stock | Award | 58% | 4,374 | 11,919 | 04 Mar 2026 | Direct | ||
| David Soergel | MDGL | Stock Option (Right to Buy) | Award | 5,467 | 5,467 | 04 Mar 2026 | Direct | |||
| Mardi Dier | MDGL | Common Stock | Sale | -11.3% | $505,389 | $427.21 | -1,183 | 9,257 | 02 Mar 2026 | Direct |
| Richard S. Levy | MDGL | Common Stock | Options Exercise | 9.92% | 2,500 | 27,697 | 23 Feb 2026 | Direct | ||
| Richard S. Levy | MDGL | Stock Option (Right to Buy) | Options Exercise | -100% | -2,500 | 0 | 23 Feb 2026 | Direct | ||
| Richard S. Levy | MDGL | Common Stock | Options Exercise | 18.9% | 4,000 | 25,197 | 26 Jan 2026 | Direct | ||
| Richard S. Levy | MDGL | Stock Option (Right to Buy) | Options Exercise | -100% | -4,000 | 0 | 26 Jan 2026 | Direct | ||
| Carole Huntsman | MDGL | Common Stock | Sale | -9.07% | $449,339 | $493.78 | -910 | 9,122 | 26 Jan 2026 | Direct |
| William John Sibold | MDGL | Common Stock | Sale | -1.05% | $776,546 | $492.42 | -1,577 | 148,497 | 26 Jan 2026 | Direct |
| Rebecca Taub | MDGL | Common Stock | Sale | -0.14% | $318,596 | $492.42 | -647 | 452,704 | 26 Jan 2026 | Direct |
| Kelley Shannon T. | MDGL | Common Stock | Sale | -7.54% | $344,173 | $497.36 | -692 | 8,481 | 20 Jan 2026 | Direct |
| Rebecca Taub | MDGL | Common Stock | Sale | -0.49% | $1,098,343 | $490.77 | -2,238 | 453,351 | 20 Jan 2026 | Direct |
| Rita Thakkar | MDGL | Common Stock | Award | 2,398 | 2,398 | 15 Jan 2026 | Direct | |||
| Rita Thakkar | MDGL | Stock Option (Right to Buy) | Award | 1,826 | 1,826 | 15 Jan 2026 | Direct | |||
| Paul A. Friedman | MDGL | Common Stock | Sale | -0.15% | $154,348 | $551.24 | -280 | 187,164 | 09 Jan 2026 | Direct |
| Paul A. Friedman | MDGL | Common Stock | Options Exercise | 0.15% | 280 | 187,444 | 09 Jan 2026 | Direct | ||
| Paul A. Friedman | MDGL | Stock Option (Right to Buy) | Options Exercise | -100% | -280 | 0 | 09 Jan 2026 | Direct | ||
| Paul A. Friedman | MDGL | Common Stock | Sale | -11.6% | $12,808,957 | $522.39 | -24,520 | 187,164 | 09 Jan 2026 | Direct |
| Paul A. Friedman | MDGL | Common Stock | Options Exercise | 13.1% | 24,520 | 211,684 | 09 Jan 2026 | Direct | ||
| Paul A. Friedman | MDGL | Stock Option (Right to Buy) | Options Exercise | -98.9% | -24,520 | 280 | 09 Jan 2026 | Direct | ||
| Rebecca Taub | MDGL | Common Stock | Sale | -0.05% | $132,080 | $550.33 | -240 | 455,589 | 09 Jan 2026 | Direct |
| Rebecca Taub | MDGL | Common Stock | Options Exercise | 0.05% | 240 | 455,829 | 09 Jan 2026 | Direct | ||
| Rebecca Taub | MDGL | Stock Option (Right to Buy) | Options Exercise | -100% | -240 | 0 | 09 Jan 2026 | Direct | ||
| Rebecca Taub | MDGL | Common Stock | Sale | -3.88% | $9,617,312 | $522.40 | -18,410 | 455,589 | 09 Jan 2026 | Direct |
| Rebecca Taub | MDGL | Common Stock | Options Exercise | 4.04% | 18,410 | 473,999 | 09 Jan 2026 | Direct | ||
| Rebecca Taub | MDGL | Stock Option (Right to Buy) | Options Exercise | -98.7% | -18,410 | 240 | 09 Jan 2026 | Direct | ||
| Paul A. Friedman | MDGL | Common Stock | Sale | -11.7% | $13,694,158 | $552.18 | -24,800 | 187,164 | 10 Dec 2025 | Direct |
| Paul A. Friedman | MDGL | Common Stock | Options Exercise | 13.2% | 24,800 | 211,964 | 10 Dec 2025 | Direct | ||
| Paul A. Friedman | MDGL | Stock Option (Right to Buy) | Options Exercise | -50% | -24,800 | 24,800 | 10 Dec 2025 | Direct | ||
| Rebecca Taub | MDGL | Common Stock | Gift | -1.18% | -5,455 | 455,589 | 10 Dec 2025 | Direct | ||
| Rebecca Taub | MDGL | Common Stock | Sale | -3.89% | $10,297,573 | $552.15 | -18,650 | 461,044 | 10 Dec 2025 | Direct |
| Rebecca Taub | MDGL | Common Stock | Options Exercise | 4.05% | 18,650 | 479,694 | 10 Dec 2025 | Direct | ||
| Rebecca Taub | MDGL | Stock Option (Right to Buy) | Options Exercise | -50% | -18,650 | 18,650 | 10 Dec 2025 | Direct | ||
| William John Sibold | MDGL | Common Stock | Sale | -1.57% | $1,380,816 | $575.34 | -2,400 | 150,074 | 04 Dec 2025 | Direct |
| William John Sibold | MDGL | Common Stock | Options Exercise | 48.8% | 50,000 | 152,474 | 03 Dec 2025 | Direct | ||
| William John Sibold | MDGL | Performance Restricted Stock Units | Options Exercise | -100% | -50,000 | 0 | 03 Dec 2025 | Direct | ||
| Mardi Dier | MDGL | Common Stock | Sale | -28.6% | $2,413,416 | $578.34 | -4,173 | 10,440 | 02 Dec 2025 | Direct |
* An asterisk sign (*) next to the price indicates that the price is likely invalid.